ClinicalTrials.gg
Active, not recruitingNCT06805877PrEDICTUpdated Sep 25, 2026

Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing

An interventional study of Predictive Analytics and Clinical Decision Support in HIV, sponsored by Harvard Pilgrim Health Care. Active, not recruiting at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Harvard Pilgrim Health Care · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Scale-up of HIV preexposure prophylaxis (PrEP) is a key strategy of the U.S. initiative to end the HIV epidemic, but healthcare providers lack tools to support PrEP discussions and prescribing for patients likely to benefit. This research will evaluate whether integrating automated tools into electronic health records to help providers efficiently and equitably identify potential candidates for PrEP, discuss PrEP, and prescribe PrEP can improve PrEP initiation and persistence in safety-net community health centers. It will achieve this by conducting a stepped-wedge trial of a decision support tool with an embedded HIV prediction model to identify patients likely to benefit from PrEP. The intervention will be delivered to healthcare providers in 16 community health centers within the national OCHIN network.

02

Conditions studied

  • HIV

Keywords

  • HIV
  • PrEP
  • pre-exposure prophylaxis
  • prevention
  • prediction model
  • clinical decision support
03

In context

Lead sponsor

Harvard Pilgrim Health Care is the lead sponsor of 35 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Delivery site saw at least 500 distinct patients in 2024 during in-person or telehealth visits
  • Delivery site had at least 10 new diagnoses or positive HIV screening tests in 2023
  • Delivery site provides primary care other than pediatrics, and the primary care department(s) were active on OCHIN Epic as of 1/1/2023

Exclusion criteria

Exclusion Criteria:

  • Delivery site specializing in or STI care
  • Correctional facilities
  • Mobile sites
  • School-based health center sites
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    Data will be extracted from EHRs of control clinics as a comparison, and those clinics will not actively participate in study activities

  • Active comparator
    Predictive analytics and clinical decision support

    Providers in enrolled intervention clinics will receive point-of-care notifications via the EHR-embedded decision support tool about patients who are at increased predicted HIV risk and therefore likely to benefit from PrEP

    Other: Predictive Analytics and Clinical Decision Support

Interventions

  • OtherPredictive Analytics and Clinical Decision Support

    The intervention will include automated EHR notifications to clinicians at 16 OCHIN community health centers about patients who are likely to benefit from PrEP. These patients will be identified by an HIV prediction model that was developed and validated during the pilot phase of this study using historical OCHIN EHR data. For patients above a preselected threshold of predicted HIV risk, clinicians will be notified at the point of care that the patient may benefit from PrEP and will be provided with EHR-based tools to support discussions and prescribing. The intervention will also include coaching on PrEP and the decision support tool, as well as project team support during the trial period.

06

What researchers measure

Primary outcomes

  1. PrEP initation

    Proportion of patients above the prediction model risk threshold without a recently active PrEP prescription (within the prior 6 months) or prior HIV diagnosis who are prescribed PrEP during the study period.

    Time frame: 30 months

Secondary outcomes

  1. PrEP persistence

    Proportion of patients prescribed PrEP who persist on PrEP for 6 and 12 months, as measured by prescription refills ordered.

    Time frame: 30 months

07

Study locations

16 sites
  • Bay Area Community Health Liberty Clinic
    Fremont, California 94538, United States
  • Lifelong East Oakland Health Center
    Oakland, California 94605, United States
  • TrueCare Oceanside Family Medicine
    Oceanside, California 92054, United States
  • DAP Legacy
    Palm Springs, California 92262, United States
  • One Community Health Midtown Campus
    Sacramento, California 95811, United States
  • Southwest Community Health Center 968 Fairfield Avenue
    Bridgeport, Connecticut 06605, United States
  • Mercy Care Decatur Street
    Atlanta, Georgia 30312, United States
  • Siouxland Community Health Center Sioux City
    Sioux City, Iowa 51105, United States
  • Lynn Community Health Center 269 Union
    Lynn, Massachusetts 01901, United States
  • Mattapan Community Health Center Blue Hill
    Mattapan, Massachusetts 02126, United States
  • Neighborhood Family Practice Ridge Community Health Center
    Cleveland, Ohio 44102, United States
  • Signature Health Painesville
    Painesville, Ohio 44077, United States
  • Variety Care Sequoyah
    Oklahoma City, Oklahoma 73112, United States
  • Prism Belmont
    Portland, Oregon 97214, United States
  • Bee Busy Wellness Center Bray Oaks
    Houston, Texas 77031, United States
  • Seattle Roots Community Health Carolyn Downs Community Clinic
    Seattle, Washington 98122, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jul 2029, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 3, 2025
StartActual
Apr 21, 2025
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2030
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date, oversight details and site details
1 update, last Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Minor edits only
    + 4 other changes: index terms, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06805877
Lead sponsor
Harvard Pilgrim Health Care
Responsible party
Julia Marcus (Associate Professor, Harvard Pilgrim Health Care) — Principal investigator
First posted
Feb 3, 2025
Start date
Apr 21, 2025
Primary completion
Jul 2029 (estimated)
Completion
Jul 2030 (estimated)
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion